Rifaximin for hepatic encephalopathy: eight opponents clear a use patent at the EPO
Published 20 November 2026 · Last reviewed 20 November 2026 · MPA Business Services
On 29 April 2025 the EPO's Technical Board of Appeal 3.3.07 dismissed Salix's appeal in T 0122/23, so the revocation of European Patent 2 350 096 is final. The patent claimed rifaximin for decreasing the risk of breakthrough episodes of hepatic encephalopathy by long-term administration of defined daily doses alongside lactulose. The Board accepted the priority claim and found the claim new, because the closest prior document was a trial protocol without results, but held it obvious: a skilled person reading the published trial design had a reasonable expectation that the regimen would succeed.
- Product
- Rifaximin 550 mg tablets for reducing recurrence of overt hepatic encephalopathy (sold as Targaxan in the UK and under other names in the EU)
- Active substance
- rifaximin
- Originator
- Salix Pharmaceuticals (Bausch Health), patentee
- Challengers
- Teva, Accord Healthcare, STADA, Alfred E. Tiefenbacher and four other opponents filing through patent attorneys or individually
- Courts
- EPO Opposition Division; EPO Technical Board of Appeal 3.3.07
- Decided
- 4 November 2022 (Opposition Division, revoked); 29 April 2025 (Board of Appeal, T 0122/23, appeal dismissed)
- Jurisdictions
- European Patent Organisation
What was decided
Rifaximin is a poorly absorbed antibiotic that stays in the gut. It was first developed in the 1980s and its original protection expired long ago. In liver disease it is used, at 550 mg twice a day and usually with lactulose, to reduce the recurrence of overt hepatic encephalopathy, the confusion and loss of consciousness caused by toxins a failing liver cannot clear. NICE recommends it for that use, and it is prescribed long term, often for life.
Salix’s European Patent 2 350 096, filed in 2009 with a 2008 priority date, claimed rifaximin for decreasing the risk of breakthrough episodes of hepatic encephalopathy by long-term administration of defined daily doses together with lactulose. Eight parties opposed it: Teva, Accord Healthcare, STADA and Alfred E. Tiefenbacher, and four others filing through patent attorneys or in their own name. The Opposition Division revoked it in November 2022. It held that the claims as granted went beyond the application as filed, and that a narrower version, limited to at least 168 days of 550 mg twice daily with lactulose, was new but obvious.
On 29 April 2025 the Technical Board of Appeal dismissed Salix’s appeal:
- Priority was valid. Under the Enlarged Board’s 2023 rulings, entitlement to priority is presumed, and the opponents had not rebutted it.
- The claim was new. The closest document was the published protocol of the pivotal trial, which described the design but gave no results, so it did not disclose that the regimen works.
- It was obvious. The question was whether a skilled person, given the trial design and what was known about rifaximin, had a reasonable expectation of success. The Board held that they did. Salix’s fallback requests had the same main claim and fell with it.
Salix had already lost a separate rifaximin dosage patent, 2 252 148, at the EPO: the Board dismissed that appeal on 9 October 2024 after Salix declined to defend any amended version.
Timeline
| Date | Event |
|---|---|
| 1980s | Rifaximin developed; original protection since expired |
| 2009 | Salix files European Patent 2 350 096 (priority 2008) |
| December 2019 | Patent granted; oppositions follow |
| November 2021 | Separate dosage patent 2 252 148 revoked by the Opposition Division |
| 4 November 2022 | Opposition Division revokes 2 350 096 |
| 14 February 2024 | Divisional 3 628 319 granted, claiming use to reduce hospitalisation |
| 9 October 2024 | Board of Appeal dismisses the appeal on the dosage patent |
| 29 April 2025 | Board of Appeal dismisses the appeal on 2 350 096; revocation final |
What it means if you are…
A generics or launch planner. The patent that most directly covered the approved use is gone across every EPO country, and the decision is final. That is not the same as a clear field. A divisional from the same family, granted in 2024 with claims to reducing hepatic-encephalopathy hospitalisations at 1,000–1,200 mg a day for a year or more, was reported as opposed, and further family applications were pending. All members of the family end in 2029 at the latest. The divisional explainer explains why a family has to be read as a whole.
A buyer or procurement team. No independent generic of the 550 mg tablet appeared on the EU or UK authorisation lists we checked: every authorisation found belonged to the originator group or its licensees. A product can stay single-source long after its molecule is off patent, because the patent that matters covers the use and the dose. When that patent falls, as here, the next questions are the divisional and the time needed to obtain an authorisation.
A parallel trader. The product is sold under different names and in different strengths across Europe, and the lower-strength tablets are authorised for gut infections such as traveller’s diarrhoea. The hepatic-encephalopathy indication belongs to the 550 mg tablet, so the source product has to match.
A patent team. The decision is a clear application of the “reasonable expectation of success” test to a claim drafted around a phase III regimen whose protocol had been published. Publishing a trial design before the results can make the regimen obvious even if the results themselves were not known.
Status and what to watch
The outcome of the opposition to divisional 3 628 319 and the progress of the remaining family applications; any national or UPC action on the divisional; and the first generic applications for the 550 mg hepatic-encephalopathy indication. MPA’s NHS prescribing data shows the size of the market in England for anyone weighing an entry.
Sources
- EPO Board of Appeal, T 0122/23 (Salix, rifaximin), decision of 29 April 2025
- EPO Board of Appeal, T 0162/22 (Salix, rifaximin dosage patent), decision of 9 October 2024 (PDF)
- EMA: list of nationally authorised medicinal products, rifaximin (PSUSA/00002642/202505)
- NICE technology appraisal TA337: rifaximin for preventing episodes of overt hepatic encephalopathy
- Explainer: second medical use patents and skinny labels
- Explainer: divisional patents and why revoking one rarely clears a product
This note is general information, not legal advice. The position for any particular product and country must be checked against the registers; that is what MPA Search is for.
The position in every country, kept current
MPA Search holds the patent, SPC, licence and price position for products across the UK and Europe, with the reference to the original record. Book a free demonstration.